MTNB
Matinas Biopharma·AMEX
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 0
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MTNB
Matinas Biopharma Holdings, Inc.
A clinical-stage biopharmaceutical company that develops various product candidates using lipid nano-crystal platform technology
1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921
--
Matinas Biopharma Holdings, Inc., a Delaware corporation, was incorporated in May 2013. The company is a clinical-stage biopharmaceutical company focused on delivering breakthrough therapies using lipid nanocrystals (LNC) platform delivery technology (LNC platform). The company is developing a range of products and developing product candidates, with an initial focus on severe fungal and bacterial infections. The company's proprietary cochlear implant delivery technology platform, licensed exclusively worldwide from Rutgers University, is specifically designed to directly target and safely deliver drugs to infected or inflamed sites. This innovative technology utilizes Cochleates nano-encapsulation of lipid crystal nanoparticles to encapsulate existing drugs, aiming to make them safer, more tolerable, less toxic and more bioavailable for oral use.
Company Financials
EPS
MTNB has released its 2025 Q3 earnings. EPS was reported at -0.4, versus the expected 0, missing expectations. The chart below visualizes how MTNB has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
